Pfizer Inc. Furnishes Details on CFO Transition
Summary
Dave Denton, Chief Financial Officer of Pfizer Inc., will step down from his role and leave the company on August 15, 2026, for a professional opportunity outside the pharmaceutical industry in consumer goods, as announced via Ex. 99.1 press release. His departure is not related to the Company's financial or operating results or any disagreements. Cecile Guegan, Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026, while Pfizer conducts a comprehensive search for a successor.
Why It Matters
The departure of a Chief Financial Officer is a significant executive change for Pfizer Inc. While Mr. Denton's move is for an external opportunity and not due to disagreements or performance issues, the appointment of an interim CFO signals a period of transition for the company's financial leadership.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how PFE traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View PFE Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000078003
- Filing Date
- Thursday, June 18, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral